AgomAb Therapeutics NV (AGMB) stock
AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 23, 2026Score 2/30
$5.82−0.10 (-1.69%)
Close on Nov 18, 2026Market cap $145.50KP/E –Yield –
AgomAb Therapeutics cash
Cash and short-term investments held at the end of each period.
AgomAb Therapeutics's cash was €86.42M at Dec 31, 2025. For fiscal 2025 it was €86.42M, down 49.6% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €86.42M | -49.6% |
| FY2024 | Dec 31, 2024 | €171.46M | +40.1% |
| FY2023 | Dec 31, 2023 | €122.40M | +342.4% |
| FY2022 | Dec 31, 2022 | €27.67M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | €86.42M | – |
| Q4 FY2024 | Dec 31, 2024 | €171.46M | – |
| Q4 FY2023 | Dec 31, 2023 | €122.40M | – |
| Q4 FY2022 | Dec 31, 2022 | €27.67M | – |
See a number that looks wrong?